

Supplementary Materials

Table S1. Symptoms and physical examination upon admission between groups

Whole cohort				Matched sample		
	1 ST week	2 nd week	p-value	1 ST week	2 nd week	p-value
Cough, n (%)	192 (65.5)	223 (77.4)	0.006	188 (65.2)	223 (77.4)	0.005
Arthromyalgias, n (%)	56 (19.1)	92 (31.9)	<0.001	54 (18.8)	92 (31.9)	<0.001
Ageusia, n (%)	39 (13.3)	64 (22.2)	0.005	39 (13.5)	64 (22.2)	0.007
Anosmia, n (%)	32 (10.9)	55 (19.1)	0.006	31 (10.8)	55 (19.1)	0.005
Sore throat, n (%)	19 (6.5)	22 (7.6)	0.587	19 (6.6)	22 (7.6)	0.627
Headache, n (%)	36 (12.3)	56 (19.4)	0.018	36 (12.5)	56 (19.4)	0.023
Fever, n (%)	225 (76.8)	243 (84.4)	0.033	221 (76.8)	243 (84.4)	0.028
Dyspnea, n (%)	200 (68.3)	187 (64.9)	0.395	198 (68.8)	187 (64.9)	0.330
Diarrhea, n (%)	77 (26.3)	105 (36.5)	0.008	76 (26.4)	105 (36.5)	0.009
Vomiting, n (%)	15 (5.1)	17 (5.9)	0.679	15 (5.2)	17 (5.9)	0.716
Abdominal pain, n (%)	11 (3.8)	11 (3.8)	0.967	11 (3.8)	11 (3.8)	1.000
Heart rate, bpm median [IQR]	89 [79-100]	95 [82-104]	0.001	89 [79-100]	95 [82-104]	0.001
Respiratory rate >20 bpm, n (%)	175 (59.7)	170 (59)	0.896	173 (60.1)	170 (59)	0.799

IQR: interquartile range.

Table S2. Lab tests upon admission between groups

Whole cohort				Matched sample		
	1 ST week	2 nd week	p-value	1 ST week	2 nd week	p-value
PaO ₂ /FiO ₂ , median [IQR]	290 [213-338]	311 [267-357]	<0.001	290 [211-333]	311 [267-357]	<0.001
Lymphocytes x10 ⁶ /L, median [IQR]	840 [580-1,175]	900 [683-1,235]	0.033	830 [580-1,178]	900 [683-1,235]	0.028
CRP mg/L, median [IQR]	98 [57-169]	112 [60-172]	0.274	97 [57-170]	112 [60-172]	0.257
LDH U/L, median [IQR]	345 [274-441]	348 [283-446]	0.657	345 [274-441]	348 [283-446]	0.673
Ferritin mcg/L, median [IQR]	931 [490-1,588]	910 [439-1,780]	0.742	927 [485-1,551]	910 [439-1,780]	0.602
D-dimer ng/mL, median [IQR]	400 [260-847]	309 [250-523]	<0.001	405 [262-855]	309 [250-523]	<0.001
1-2 high-risk criteria, n (%)	209 (71.3)	214 (74.3)	0.420	206 (71.5)	214 (74.3)	0.453
≥ 3 high-risk criteria, n (%)	84 (28.7)	74 (25.7)	0.420	82 (28.5)	74 (25.7)	0.453

CRP: C-reactive protein. LDH: lactate dehydrogenase. IQR: interquartile range.

Table S3. Treatments between groups

Whole cohort				Matched sample		
	1 ST week	2 nd week	p-value	1 ST week	2 nd week	p-value
Remdesivir	147 (50.2)	60 (20.8)	<0.001	147 (51)	60 (20.8)	<0.001
Tocilizumab	75 (25.6)	73 (25.3)	0.945	72 (25)	73 (25.3)	0.924
LMWH			0.035			0.026
No	28 (9.6)	25 (8.7)		28 (9.7)	25 (8.7)	
Low doses	146 (49.8)	174 (60.4)		142 (49.3)	174 (60.4)	
Intermediate doses	71 (24.2)	61 (21.2)		70 (24.3)	61 (21.2)	
Full doses	48 (16.4)	28 (9.7)		48 (16.7)	28 (9.7)	

LMWH: Low-molecular-weight heparin.

Table S4. Outcomes between groups in patients with 1-2 high-risk criteria

Whole cohort				Matched sample		
	1 ST week	2 nd week	p-value	1 ST week	2 nd week	p-value
Primary outcome n (%)						
In-hospital mortality	50 (23.9)	18 (8.4)	<0.001	50 (24.3)	18 (8.4)	<0.001
Secondary outcomes n (%)						
HFNC	85 (40.7)	63 (29.4)	0.015	85 (41.3)	63 (29.4)	0.011
NIMV	50 (23.9)	36 (16.8)	0.070	50 (24.3)	36 (16.8)	0.059
IMV	28 (13.4)	17 (7.9)	0.069	28 (13.6)	17 (7.9)	0.061
ICU admission	40 (19.1)	30 (14)	0.157	40 (19.4)	30 (14)	0.138

HFNC: high-flow nasal cannula. NIMV: non-invasive mechanical ventilation. IMV: invasive mechanical ventilation. ICU: intensive care unit

Table S5. Outcomes between groups in patients with 3-4-5 high-risk criteria

	Whole cohort			Matched sample		
	1 st week	2 nd week	p-value	1 st week	2 nd week	p-value
Primary outcome n (%)						
In-hospital mortality	35 (41.7)	19 (25.7)	0.034	35 (42.7)	19 (25.7)	0.026
Secondary outcomes n (%)						
HFNC	43 (51.2)	44 (59.5)	0.297	43 (52.4)	44 (59.5)	0.378
NIMV	40 (47.6)	24 (32.4)	0.052	40 (48.8)	24 (32.4)	0.038
IMV	28 (33.3)	20 (27)	0.390	28 (34.1)	20 (27)	0.336
ICU admission	39 (46.4)	23 (31.1)	0.049	39 (47.6)	23 (31.1)	0.036

HFNC: high-flow nasal cannula. NIMV: non-invasive mechanical ventilation. IMV: invasive mechanical ventilation. ICU: intensive care unit